1.INTRODUCTION
In this report, ASKCI analyzes the financial assessment and credit risk of biological medicine industry. It will provide you with a comprehensive understanding of this industry from the following aspects: development scale, operating benefit, related policies and industry analysis of major regions and provinces, etc., as well as make scientific prediction on the future development biological medicine industry.
1)The Aim of this report
To provide readers with comprehensive & in-depth understanding of financial situation and credit risk on China’s biological medicine industry;
-To understand position of the biological medicine industry in China;
-To get more information of the major biological medicine produced regions;
-To predict what future of China’s biological medicine industry will be;
-To find out the region be worth for investment and the investment risks of biological medicine industry in China;
-To reveal opportunities in Chinese biological medicine industry.
2)Benefit from the report
-Obtain latest financial information of biological medicine industry in China, such as enterprise scale, total asset, sale revenue, total profit and so on;
-Evaluate the status of the biological medicine industry in China;
-Identify key trends and opportunities in China’s biological medicine industry;
-Give the future prospects of China’s biological medicine industry , and point out some investment risks it will face;
-Find out some regions where are best worth for investment in China’s biological medicine industry.
3)Deliverables
Word-format report, with around 30-50 pages;
Excel-format database of key regions and provinces of biological medicine industry;
4)Time needed
3 weeks needed
2. SCOPE OF INVESTIGATION
The report will investigate Chinese biological medicine industry from the following aspects:
-Development analysis (Industry scale, Industry cost, etc.)
-Operation situation (Debt paying ability, operation ability, etc.)
-Major areas (major regions and top 5 provinces)
-Future forecast
-Commercial opportunity
'
3. MAIN CONTENT
Part Contents
1 Overview and policy of biological medicine industry in China
1.1 Overview of biological medicine industry
1.1.1 Industry definition
1.1.2 Industry life cycle
1.1.3 Industry status in national economy
1.2 Policy of biological medicine industry
1.2.1 Policy on biological medicine industry
1.2.2 Policy on upstream and downstream industry
2 Development scale of China's biological medicine industry
2.1 Industry scale analysis of biological medicine industry in 2011-2015
2.1.1 Enterprise scale
2.1.2 Total asset
2.1.3 Sales revenue
2.1.4 Total profit
2.2 Industry cost analysis of biological medicine industry in 2011-2015
2.2.1 Sale cost
2.2.2 Sales expense
2.2.3 Administration expense
2.2.4 Financial expense
3 Operating benefit analysis of biological medicine industry
3.1 Debt paying ability analysis of biological medicine industry in 2011-2015
3.1.1 Debt scale
3.1.2 Debt-to-assets ratio
3.2 Profitability analysis of biological medicine industry in 2011-2015
3.2.1 Ratio of profits to cost
3.2.2 Gross profit to sales
3.2.3 Profit ratio of sales
3.2.4 Return on asset
3.3 Operation ability analysis biological medicine industry in 2011-2015
3.3.1 Total assets turnover
3.3.2 Current asset turnover
3.3.3 Receivables turnover
4 Biological medicine industry analysis in major regions
4.1 East China
4.1.1 Company number
4.1.2 Asset and liability
4.1.3 Sale revenue
4.1.4 Total profit
4.2 Central China
…… ……
4.5 South China
4.8.1 Company number
4.8.2 Asset and liability
4.8.3 Sale revenue
4.8.4 Total profit
5 Biological medicine industry analysis in Top 5 provinces
5.1 Province A
5.1.1 Enterprise scale
5.1.2 Total asset
5.1.3 Sales revenue
5.1.4 Total profit
5.1.5 Profitability analysis
5.1.6 Operation ability analysis
5.2 Province B
…… ……
5.5 Province E
6 Future forecast of biological medicine industry in China
6.1 Investment prospects
6.1.1 Development prospect analysis
6.1.2 Industry sale revenue forecast 2016 to 2020
6.1.3 Industry total profit forecast 2016 to 2020
6.2 Investment risk analysis
6.2.1 Industry policy risk
6.2.2 Raw material market risk
6.2.3 Market competition risk
6.2.4 Technology risk
6.3 Investment advices
List of Figures
Figure 1.1.2-1 Industry life cycle of biological medicine industry in China
Figure 2.1.1-1 Enterprise scale distribution of China’s biological medicine industry, 2015
Figure 2.1.2-1 Total asset of biological medicine industry in China, 2011-2015
Figure 2.1.3-1 Sales revenue of biological medicine industry in China, 2011-2015
Figure 2.1.4 Total profit of biological medicine industry in China, 2011-2015
......
List of Tables
Table 1.2.1-1 Policy on biological medicine industry in China, 2010-2016
Table 3.2.1-1 Ratio of profits to cost of biological medicine industry in China, 2011-2015
Table 3.2.2-1 Gross profit to sales of biological medicine industry in China, 2011-2015
Table 3.2.3-1 Profit ratio of sales of biological medicine industry in China, 2011-2015
......
